MK-677

MK-677 (Ibutamoren) is an orally active ghrelin mimetic that stimulates sustained GH and IGF-1 increases with once-daily dosing. It is technically not a peptide but is widely used in the peptide community for muscle, sleep, and anti-aging applications.

MK-677 (ibutamoren, ibutamoren mesylate; development code MK-0677; also designated L-163,191) is a non-peptide, orally bioavailable spiroindoline compound that acts as a potent, selective, and long-acting ghrelin receptor agonist. It is classified as a growth hormone secretagogue (GHS) because its primary pharmacological effect is to stimulate pulsatile growth hormone (GH) release from the anterior pituitary — an action it achieves by mimicking the endogenous hunger hormone ghrelin at the growth hormone secretagogue receptor 1a (GHSR-1a).

Unlike injectable GH-releasing peptides (GHRPs) such as GHRP-6 or hexarelin, which are administered subcutaneously multiple times per day, MK-677 is taken orally once daily. Its plasma half-life of approximately 24 hours allows for sustained elevation of GH and insulin-like growth factor 1 (IGF-1) with a single dose, more closely approximating the GH profile of healthy young adults in older populations where GH secretion has declined with age (somatopause). This oral convenience — combined with the combination of GH axis stimulation, improved sleep quality, and perceived improvements in body composition — has made MK-677 one of the most widely self-administered research chemicals in biohacker and fitness communities despite having no FDA approval for any indication.

Structurally, MK-677 was originally discovered and developed by Merck & Co., Inc. through the 1990s and 2000s as a potential treatment for muscle-wasting conditions, osteoporosis, and growth hormone deficiency in elderly populations. Although it advanced through phase 2 and one phase 3 trial, Merck discontinued development after a cardiac safety study in elderly patients was terminated early due to an excess of congestive heart failure events in the MK-677 group (6.5% vs 1.7% placebo), contributing to the company's decision not to pursue FDA approval. The compound is not a peptide and is therefore not subject to the 2023 FDA final rule restricting peptide compounding, but the FDA has issued warning letters to supplement manufacturers marketing it for human consumption. It is prohibited by the World Anti-Doping Agency (WADA) under S2 (peptide hormones, growth factors, related substances) and is classified as an unapproved new drug when sold for human use in the United States.

Interest in MK-677 persists because no other oral compound has demonstrated comparable GH-axis activation in humans, and because the sleep architecture improvements documented in clinical trials — particularly the nearly 50% increase in slow-wave (stage IV) and REM sleep — are unique pharmacological properties not shared by any approved agent.

MK-677 produces its effects primarily through full agonism at the growth hormone secretagogue receptor 1a (GHSR-1a), the endogenous receptor for ghrelin. GHSR-1a is a class A G-protein-coupled receptor expressed in the hypothalamus (arcuate nucleus, ventromedial nucleus), pituitary somatotrophs, hippocampus, vagal neurons, and multiple peripheral tissues. When MK-677 binds GHSR-1a in hypothalamic neurons, it triggers the release of growth hormone-releasing hormone (GHRH), which then travels via the portal circulation to the anterior pituitary where it binds to the GHRH receptor and stimulates GH secretion. Simultaneously, MK-677 acts directly on pituitary somatotrophs expressing GHSR-1a to amplify GH pulse amplitude.

The net result of this dual hypothalamic and pituitary action is a preservation and amplification of pulsatile GH secretion — the natural pattern by which GH is released in bursts primarily during the first hour of slow-wave sleep. Multiple clinical studies have confirmed that a single oral dose of MK-677 (25 mg) increases mean 24-hour GH concentrations by approximately 97% and IGF-1 by 40–60% relative to baseline, restoring levels observed in young healthy adults within populations where GH axis activity has declined due to aging. This is mechanistically distinct from exogenous GH injection, which suppresses endogenous GH through negative feedback; MK-677 instead preserves or enhances the pulsatile pattern while respecting the hypothalamic-pituitary negative-feedback loop.

The GHSR-1a pathway has important downstream effects beyond GH secretion. In the hypothalamus, GHSR-1a activation mediates orexigenic signaling — stimulating appetite through NPY/AgRP neurons in the arcuate nucleus and by activating reward circuits in the nucleus accumbens. This appetite-stimulating effect is a clinically significant side effect, explaining the characteristic "MK-677 hunger" reported by most users, and has relevance to its investigated use in cachexia and anorexia states. In the CNS more broadly, ghrelin receptor signaling influences memory consolidation, anxiety regulation, and dopaminergic neurotransmission, which may contribute to the cognitive and mood effects some users report.

In adipose tissue, MK-677 indirectly increases GH signaling, which promotes lipolysis in the fasted state and inhibits insulin-stimulated glucose uptake (contributing to the insulin resistance and fasting hyperglycemia observed clinically). In bone, the GH/IGF-1 axis stimulated by MK-677 activates bone remodeling through IGF-1-mediated osteoblast proliferation and differentiation. In skeletal muscle, IGF-1 promotes protein synthesis and nitrogen retention, which is responsible for the lean mass increases documented in elderly trial populations — though the proportion of lean mass gain attributable to water versus contractile protein has been debated.

MK-677 has been evaluated in more clinical research than almost any other research chemical in widespread use, yet it remains unapproved due to a combination of modest efficacy for its primary target indications, the cardiac safety signal in elderly populations, and Merck's commercial decision to deprioritize the program.

**GH/IGF-1 activation: Chapman et al. 1996 (JCEM).** One of the earliest systematic dose-finding studies showed that a single oral dose of MK-677 25 mg increased mean 24-hour GH concentrations by approximately 97% and IGF-1 levels in a dose-dependent manner. These results confirmed that the compound could restore GH pulsatility to levels observed in young adults in populations where GH axis activity had declined. The two-week study also documented the major side effects: increased appetite, water retention, and mild edema.

**Sleep quality: Murphy et al. 1998 (Neuroendocrinology).** A randomized crossover study in both young and elderly subjects measured sleep architecture via polysomnography. MK-677 (25 mg nightly for 1 week) increased stage IV slow-wave sleep duration by approximately 50% and REM sleep duration by more than 20% compared to placebo in young subjects. In older adults, treatment was associated with a nearly 50% increase in REM sleep and decreased REM latency. The sleep benefit is mechanistically consistent with the known role of GH release — which occurs predominantly during slow-wave sleep — in sleep architecture regulation. These are the strongest objective sleep quality data for any growth hormone secretagogue.

**Body composition: Nass et al. 2008 (Annals of Internal Medicine).** This was a 24-month, randomized, double-blind, placebo-controlled modified crossover trial in 65 healthy adults aged 60–81. Daily MK-677 25 mg significantly increased GH and IGF-1 levels to those of healthy young adults. Fat-free mass increased by 1.1 kg in the MK-677 group versus a decrease of 0.5 kg in placebo (p<0.001). Body cell mass (intracellular water plus cell solids) also increased. However, no change in muscle strength or physical function was observed, raising the question of whether the lean mass increase represented new contractile protein or intracellular water redistribution. Changes in bone mineral density were inconsistent across skeletal sites. Average fasting blood glucose rose approximately 5 mg/dL, consistent with GH-mediated insulin resistance.

**Cardiac safety and early termination.** A phase 3 trial in frail elderly adults examining MK-677's ability to prevent hip fracture and maintain muscle function was terminated early due to a significantly higher rate of congestive heart failure in the MK-677 arm (6.5%) compared to placebo (1.7%). This signal — likely reflecting GH/IGF-1-mediated fluid retention in a population with pre-existing cardiac vulnerability — was the primary reason Merck discontinued the development program and contributed to the FDA's subsequent warning letters against human use marketing. This cardiac risk appears to be population-specific (frail elderly with pre-existing cardiac disease) rather than a class-wide contraindication, but it underscores the importance of caution in any cardiovascular risk patient and the absence of long-term safety data in younger healthy populations.

**Cancer and IGF-1 concern.** MK-677 chronically elevates IGF-1, a mitogenic growth factor that activates the PI3K/Akt/mTOR pathway in both normal and neoplastic cells. Epidemiological studies have associated chronically elevated endogenous IGF-1 with increased risk of prostate, colorectal, and breast cancers. While no human clinical trial has directly documented MK-677-induced cancer, the theoretical risk is considered clinically meaningful, and MK-677 use is generally considered contraindicated in individuals with a personal or family history of hormone-sensitive malignancies.[1][2][3][4][5][6]

Peptides commonly paired with MK-677 for synergistic effects.